Formuepleje A S Boosts Position in IQVIA Holdings Inc. $IQV

Formuepleje A S raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 29.3% during the 2nd quarter, Holdings Channel reports. The firm owned 23,265 shares of the medical research company’s stock after acquiring an additional 5,278 shares during the quarter. Formuepleje A S’s holdings in IQVIA were worth $4,495,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in IQV. Brighton Jones LLC boosted its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC increased its holdings in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter worth about $514,000. First Trust Advisors LP raised its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. upped their target price on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Stifel Nicolaus increased their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Stock Performance

NYSE:IQV opened at $267.34 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market cap of $44.00 billion, a PE ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18. The firm has a 50 day simple moving average of $230.54 and a 200-day simple moving average of $192.84. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $271.80.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business earned $2.81 earnings per share. IQVIA’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.